Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Isa-VRd shows greater efficacy compared to VRd in intransplant-ineligible NDMM...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Isa-VRd shows greater efficacy compared to VRd in intransplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Daratumumab-based maintenance regimens show favourable responses in ransplant...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Daratumumab-based maintenance regimens show favourable responses in ransplant-eligible NDMM ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Tailored to fit: New approaches in transplant-ineligible NDMM

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Tailored to fit: New approaches in transplant-ineligible NDMM ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Advancements in minimal residual disease detection in myeloma

Dr Dory Abelman - University of Toronto, Ontario, Canada

Advancements in minimal residual disease detection in myeloma ( Dr Dory Abelman - University of Toronto, Ontario, Canada )

Novel biomarkers in myeloma: CTCs and cfDNA

Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain

Novel biomarkers in myeloma: CTCs and cfDNA ( Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

More from ecancer